![](https://www.mintz.com/sites/default/files/styles/banner/public/media/images/2018-05-10/Viewpoint-Landing_Health_Care_Mintz.jpg?itok=GJq7ZUWE)
Health Care
Viewpoints
Filter by:
Health Care Enforcement Review and 2018 Outlook: Criminal and Civil Enforcement Trends
January 8, 2018 | Blog | By Eoin Beirne, Samantha Kingsbury, Karen Lovitch
In both civil and criminal enforcement proceedings, 2017 was perhaps most notable for the cases brought against individual health care providers and small physician practice owners.
Read more
ML Strategies - 2018 Health Care Preview
January 4, 2018 | Blog
2017 was an eventful year for health care, and now we can all sit back and relax with very little concern that major health policy will be on the table in 2018. Right? Not so fast. Talks of entitlement reform, upcoming regulatory action in Medicare, Medicaid, FDA and the Marketplace, and let's not forget the still lingering health care minibus. Lots to do in 2018 and we are just getting started.
Read more
Health Care Enforcement Year in Review and 2018 Outlook: The False Claims Act’s Materiality Standard as Established by Escobar Continues to Evolve
January 4, 2018 | Blog | By Laurence Freedman
Throughout 2017, the lower courts built upon the standard for determining immateriality under the False Claims Act (FCA) established by the U.S. Supreme Court in Universal Health Servs., Inc. v. United States ex rel. Escobar, 136 S. Ct. 1989 (2016) (“Escobar”).
Read more
Sessions Memo Resets Federal Marijuana Enforcement Policy
January 4, 2018 | Blog | By Daria Niewenhous
The U. S. Department of Justice (DOJ) issued a memo dated January 4, 2018 regarding federal marijuana enforcement policy, directing all U.S. Attorneys to enforce the laws enacted by Congress and to follow well-established principles when pursuing prosecutions related to marijuana activities.
Read more
Health Care Enforcement Year in Review and 2018 Outlook: Major Case Law Developments
January 3, 2018 | Blog | By Brian Dunphy
Like prior years, 2017 saw large government recoveries and a high volume of False Claims Act (“FCA”) cases, which remain the government’s primary health care enforcement tool.
Read more
Health Care Enforcement Year in Review and 2018 Outlook: Trends In Health Care False Claims Act Cases
January 2, 2018 | Blog | By Kevin McGinty
The volume of health care–related qui tam litigation under the False Claims Act (FCA) remained robust in 2017. Based on our review of the data in Mintz Levin's Health Care Qui Tam Database, we identified over 150 qui tam lawsuits that were unsealed in the twelve months ended November 30, 2017.
Read more
ML Strategies Health Care Preview - Week of January 2nd
January 2, 2018 | Blog
Happy New Year and welcome to 2018! Our first weekly preview of the year dives into the issues left unresolved in 2017. Where does CHIP and the minibus fit into the developing government funding bill, which Congress will have to finalize or pass another continuing resolution by January 19th.
Read more
FDA 2017 Year in Review: Refining Medical Device Pathways and Introducing Pilot Programs to Promote Quality
December 26, 2017 | Blog | By Benjamin Zegarelli
This is the third installment of our year-in-review series covering major developments at FDA. While the previous two installments pertain to FDA actions on drugs and biologics, this post will address developments related to “traditional” medical devices and diagnostics (i.e., not software devices).
Read more
Bah, Humbug! HIPAA Compliance Isn’t Getting Any Easier
December 21, 2017 | Blog | By Dianne Bourque, Ellen Janos
As we look back on 2017, one message is clear: don’t be a Scrooge when it comes to HIPAA compliance. With ever-evolving security threats and unrelenting enforcement, regulated entities must maintain a spirit of compliance that lasts the whole year through.
Read more
FDA 2017 Year in Review: Therapeutic Products, Part 2
December 19, 2017 | Blog | By Joanne Hawana
Yesterday we started off our year-end series of blog posts with the first part of a review of FDA’s actions for 2017 in the therapeutic products space. Part 1 recapped Commissioner Gottlieb’s initiative to tackle drug competition issues, with the end goal of affecting drug prices, as well as current figures related to this year's new drug and biologic approvals.
Read more
ML Strategies Health Care Preview - Week of December 18th
December 18, 2017 | Blog
Republicans enter this week on target to pass a sweeping tax reform package after securing support from Senators Corker (TN) and Rubio (FL). Additionally Susan Collins (ME) applauded the “inclusion of multiple amendments,” but stopped short of publicly supporting the measure.
Read more
FDA 2017 Year In Review: Therapeutic Products Energized by Cures Act, Bold Leadership
December 18, 2017 | Blog | By Joanne Hawana
As is the tradition here at Health Law & Policy Matters, towards the end of the year we take stock of what transpired in our respective industries and highlight important legal, regulatory, and business developments. For those of us who monitor the Food and Drug Administration (FDA or the Agency) and counsel FDA-regulated entities, it has certainly been a whirlwind of a year.
Read more
Mintz’s Health Care Enforcement Defense Group Publishes New Qui Tam Update
December 14, 2017 | Blog | By Samantha Kingsbury
Earlier this week, Mintz Levin’s Health Care Enforcement Defense Group published its most recent Health Care Qui Tam update. This update covers 34 health care-related qui tam cases that were unsealed in July 2017.
Read more
Proposed Law Would Criminalize Failures to Report Data Breaches
December 12, 2017 | Blog | By Dianne Bourque, Ryan Cuthbertson
A draft bill recently introduced in the U.S. Senate serves as a good reminder that compliance with data breach reporting requirements is critical.
Read more
ML Strategies Health Care Preview - Week of December 11th
December 11, 2017 | Blog
This week, Republicans will ramp up efforts to pass a tax reform package. We should also get signs that a year-end spending deal is coming together. How things play out this week -- both inside and outside the Beltway -- will have implications for taxes, health care, and funding the government.
Read more
Proposed Medicare Advantage and Part D Regulations for CY 2019 – CMS Takes on the Opioid Epidemic
December 5, 2017 | Blog | By Bridgette Keller
Americans today are facing an opioid epidemic that stems in part from the misuse of prescription drugs. CMS takes aim at this crisis in its CY 2019 Medicare Advantage and Part D Proposed Rule (Proposed Rules) by setting out a framework for Part D plans to monitor and reduce the potential misuse of frequently abused prescription drugs.
Read more
ML Strategies Weekly Health Care Preview – Week of December 4th
December 4, 2017 | Blog
Following weekend passage of the Senate tax bill, we return this week with Congress needing to pass a government-spending bill. While it’s widely expected that this will be a two-week continuing resolution (CR), giving lawmakers time to hash out a long-term deal, a short-term extension still requires Democratic votes since spending measures can be filibustered (e.g., October 2013).
Read more
Fifth Circuit Limits FCA Liability Due to Lack of “Materiality” in Highway Guardrails Case
November 30, 2017 | Blog | By Laurence Freedman, Samantha Kingsbury
Earlier this week we released a Health Care Enforcement Advisory about a recent decision from the U.S. Court of Appeals for the Fifth Circuit that may have a significant impact on the element of “materiality” in False Claims Act (FCA) cases.
Read more
Proposed Medicare Advantage and Part D Regulations for CY 2019 - CMS Tries to Clarify Any Willing Pharmacy Rules
November 29, 2017 | Blog | By Lauren Moldawer, Tara E. Dwyer
Medicare Part D plan sponsors and pharmacies are often confused by the program's any willing pharmacy (AWP) requirements while allowing any pharmacy willing to accept the terms and conditions to participate in the sponsor’s network (AWP Requirements).
Read more
Proposed Medicare Advantage and Part D Regulations for CY 2019 - CMS Takes Aim at Drug Prices
November 27, 2017 | Blog | By Tara E. Dwyer
The rising cost of drugs in the U.S. is frequently in the news. So it is not surprising that in its contract year 2019 Proposed Medicare Advantage and Part D Regulations (Proposed Rule), the Centers for Medicare & Medicaid Services (CMS) seeks to address Part D drug prices.
Read more
Explore Other Viewpoints:
- Antitrust
- Appellate
- Arbitration, Mediation & Alternate Dispute Resolution
- Artificial Intelligence
- Awards
- Bankruptcy & Restructuring
- California Land Use
- Class Action
- Complex Commercial Litigation
- Construction
- Consumer Product Safety
- Cross-Border Asset Recovery
- Debt Financing
- Direct Investing (M&A)
- Diversity
- EB-5 Financing
- Education & Nonprofits
- Employment
- Energy & Sustainability
- Environmental Enforcement Defense
- Environmental Law
- FDA Regulatory
- Federal Circuit Appeals
- Financial Institution Litigation
- Government Law
- Growth Equity
- Health Care
- Health Care Compliance, Fraud and Abuse, & Regulatory Counseling
- Health Care Enforcement & Investigations
- Health Care Transactions
- Health Information Privacy & Security
- IP Due Diligence
- IPRs & Other Post Grant Proceedings
- Immigration
- Insolvency & Creditor Rights Litigation
- Institutional Investor Class Action Recovery
- Insurance & Financial Services
- Insurance Consulting & Risk Management
- Insurance and Reinsurance Problem-Solving & Dispute Resolution
- Intellectual Property
- Investment Funds
- Israel
- Licensing & Technology Transactions
- Life Sciences
- Litigation & Investigations
- M&A Litigation
- ML Strategies
- Medicare, Medicaid and Commercial Coverage & Reimbursement
- Mergers & Acquisitions
- Patent Litigation
- Patent Prosecution & Strategic Counseling
- Pharmacy Benefits and PBM Contracting
- Portfolio Companies
- Privacy & Cybersecurity
- Private Client
- Private Equity
- Pro Bono
- Products Liability & Complex Tort
- Projects & Infrastructure
- Public Finance
- Real Estate Litigation
- Real Estate Transactions
- Real Estate, Construction & Infrastructure
- Retail & Consumer Products
- Securities & Capital Markets
- Securities Litigation
- Special Purpose Acquisition Company (SPACs)
- Sports & Entertainment
- State Attorneys General
- Strategic IP Monetization & Licensing
- Tax
- Technology
- Technology, Communications & Media
- Technology, Communications & Media Litigation
- Trade Secrets
- Trademark & Copyright
- Trademark Litigation
- Value-Based Care
- Venture Capital & Emerging Companies
- White Collar Defense & Government Investigations
- Women's Health and Technology